Tetra Therapeutics and Shionogi Expand their Existing 2018 Collaboration to Develop and Commercialize BPN14770

 Tetra Therapeutics and Shionogi Expand their Existing 2018 Collaboration to Develop and Commercialize BPN14770

Tetra Therapeutics and Shionogi Expand their Existing 2018 Collaboration to Develop and Commercialize BPN14770

Shots:

  • The companies collaborate to develop and commercialize BPN14770 for AD, Fragile X syndrome and other indications marked by cognitive and memory deficits. Shionogi has increased its equity investment in Tetra to 50% and has an option to acquire the remaining equity if certain conditions are met based on the results of P-II PICASSO AD study assessing BPN14770 in patients with early AD
  • In 2018, the companies collaborated for BPN14770, under which Shionogi got rights for the therapy in Japan, Taiwan and Korea while Tetra has received $40M as upfront including equity investment and licensing payment along with $120M as milestones & royalties on sales of the therapy
  • BPN14770 is a novel therapy targeting PDE4D to enhance memory formation in children and older adults and has received the FDA’s ODD to treat Fragile X syndrome. Tetra is evaluating the therapy in P-II PICASSO AD study and an investigational P-II study in patients with AD & Fragile X syndrome respectively

Click here ­to­ read full press release/ article | Ref: Tetra Therapeutics | Image: Shionogi

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post